Galapagos is dedicated to conducting clinical trials that accurately measure the safety and efficacy of its candidate drugs. The Company abides by the highest ethical standards in conducting its clinical research, as described by the World Medical Association in the Declaration of Helsinki. Galapagos designs its trials to deliver robust and relevant data to understand how its products can have the most meaningful impact in the most appropriate patient populations. In due course, Galapagos believes these data will provide patients and their physicians with the information they need to make informed treatment decisions.
Galapagos conducts Phase 1 trials in healthy volunteers in centers which are specifically equipped for this purpose, with the aim to test the safety, tolerability and pharmacokinetics of the candidate drug. In cases where the Phase 1 outcome is positive, Galapagos has initiated Phase 2 studies to measure efficacy, which are conducted in patients. These studies are performed by medical doctors who are specialists in the disease area. Galapagos is not allowed to be in any way involved in volunteer/patient recruitment and enrollment for the clinical trials conducted by the Company: whether or not an individual can be included in a clinical study is decided only by the responsible medical doctors after having checked numerous eligibility criteria. In each case, Galapagos cannot and will not influence the specialists' decisions for such inclusion. The patient should contact his/her treating physician, who can then investigate with the clinical study centers the possibility for the patient to be included in a clinical study.
Information about ongoing clinical trials for Galapagos’ candidate drugs is available at clinicaltrials.gov, a service of the U.S. National Institutes of Health that provides details on clinical trials conducted worldwide.
For more information about ongoing clinical trials for GLPG0634, please click here.
For more information about ongoing clinical trials for GLPG0974, please click here.